

Karen Onel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2988092/publications.pdf>

Version: 2024-02-01

76
papers

2,657
citations

185998

28
h-index

197535

49
g-index

78
all docs

78
docs citations

78
times ranked

2300
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter Study of Utility and Acceptability of Depression and Anxiety Screening in Adolescents and Young Adults With <scp>Childhoodâ€œOnset</scp> Systemic Lupus. Arthritis Care and Research, 2023, 75, 724-733.	1.5	3
2	International Consensus for the Dosing of Corticosteroids in <scp>Childhoodâ€œOnset</scp> Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis and Rheumatology, 2022, 74, 263-273.	2.9	14
3	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis and Rheumatology, 2022, 74, 570-585.	2.9	11
4	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2022, 74, 553-569.	2.9	68
5	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Care and Research, 2022, 74, 505-520.	1.5	15
6	Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology, 2022, 20, 18.	0.9	6
7	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2022, 74, 521-537.	1.5	27
8	Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives. Annals of Medicine, 2022, 54, 1839-1850.	1.5	10
9	Lyme disease presenting as persistent severe photophobia. Journal of AAPOS, 2021, 25, 52-54.	0.2	0
10	Engaging patients and parents to improve mental health intervention for youth with rheumatological disease. Pediatric Rheumatology, 2021, 19, 19.	0.9	12
11	Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology, 2021, 19, 122.	0.9	7
12	Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group. Seminars in Arthritis and Rheumatism, 2021, 51, 957-961.	1.6	7
13	Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology, 2021, 73, 1898-1909.	2.9	19
14	Juvenile Idiopathic Arthritis Treatment Updates. Rheumatic Disease Clinics of North America, 2021, 47, 545-563.	0.8	8
15	Update on Juvenile Spondyloarthritis. Pediatrics in Review, 2021, 42, 581-589.	0.2	1
16	Chronic recurrent multifocal osteomyelitis: diagnosis and treatment. Current Opinion in Pediatrics, 2021, 33, 90-96.	1.0	13
17	1501â€œ...Genetics of age at systemic lupus erythematosus diagnosis. , 2021, , ,		0
18	503â€œ...Developing a standardized steroid dosing regimen in pediatric proliferative lupus nephritis. , 2021, ,		0

#	ARTICLE	IF	CITATIONS
19	Glitches in the utilization of telehealth in pediatric rheumatology patients during the COVID-19 pandemic. <i>Pediatric Rheumatology</i> , 2020, 18, 78.	0.9	9
20	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1945-1951.	2.9	28
21	Gaps in Mental Health Care for Youth With Rheumatologic Conditions: A Mixed Methods Study of Perspectives From Behavioral Health Providers. <i>Arthritis Care and Research</i> , 2019, 71, 591-601.	1.5	24
22	Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey. <i>Pediatric Rheumatology</i> , 2019, 17, 48.	0.9	11
23	Emergent high fatality lung disease in systemic juvenile arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1722-1731.	0.5	122
24	American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 579-590.	1.5	15
25	Mucosal-associated Lymphoid Tissue (MALT) Lymphoma in Association With Pediatric Primary Sjogren Syndrome: 2 Cases and Review. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 413-416.	0.3	14
26	Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 1117-1126.	1.0	13
27	FRIO019...URINARY TRANSCRIPTS AS BIOMARKERS OF LUPUS NEPHRITIS. , 2019, , .		0
28	92...Engaging patients and parents to improve mental health for youth with systemic lupus erythematosus. , 2019, , .		0
29	Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus. <i>Pediatric Nephrology</i> , 2019, 34, 117-128.	0.9	31
30	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. <i>Arthritis and Rheumatology</i> , 2019, 71, 451-459.	2.9	36
31	Challenges to Practicing Pediatric Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 67-78.	0.8	0
32	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 1508-1518.	2.9	26
33	Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions. <i>Arthritis Care and Research</i> , 2018, 70, 1228-1237.	1.5	128
34	Pediatric Rheumatology Collaborative Study Group " over four decades of pivotal clinical drug research in pediatric rheumatology. <i>Pediatric Rheumatology</i> , 2018, 16, 45.	0.9	35
35	Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance. <i>Journal of Rheumatology</i> , 2017, 44, 352-360.	1.0	31
36	Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. <i>Journal of Pediatrics</i> , 2017, 184, 38-44.e1.	0.9	48

#	ARTICLE	IF	CITATIONS
37	Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. <i>Pediatric Rheumatology</i> , 2017, 15, 23.	0.9	41
38	Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults. <i>Arthritis Care and Research</i> , 2016, 68, 1003-1011.	1.5	54
39	Identifying Targets for Improving Mental Healthcare of Adolescents with Systemic Lupus Erythematosus: Perspectives from Pediatric Rheumatology Clinicians in the United States and Canada. <i>Journal of Rheumatology</i> , 2016, 43, 1136-1145.	1.0	27
40	Validation of the Lupus Nephritis Clinical Indices in Childhood Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016, 68, 195-202.	1.5	27
41	Novel Method to Collect Medication Adverse Events in Juvenile Arthritis: Results From the Childhood Arthritis and Rheumatology Research Alliance Enhanced Drug Safety Surveillance Project. <i>Arthritis Care and Research</i> , 2015, 67, 529-537.	1.5	8
42	Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 191-197.	0.8	26
43	Adding Canakinumab to the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Systemic Juvenile Idiopathic Arthritis: Comment on the Article by DeWitt et al. <i>Arthritis Care and Research</i> , 2014, 66, 1430-1431.	1.5	28
44	Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for New Onset Polyarticular Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1063-1072.	1.5	101
45	A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America. <i>Pediatric Rheumatology</i> , 2014, 12, 24.	0.9	20
46	Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry. <i>Pediatric Rheumatology</i> , 2014, 12, 29.	0.9	25
47	Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 401-406.	0.5	23
48	Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. <i>Pediatric Rheumatology</i> , 2013, 11, 29.	0.9	69
49	Long-Term Safety and Efficacy of Riloncept in Patients With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2486-2496.	6.7	109
50	Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 745-752.	1.5	126
51	Inactive disease and remission in childhood onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012, 64, 683-693.	1.5	34
52	Consensus treatment plans for new onset systemic juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1001-1010.	1.5	172
53	Tumor necrosis factor inhibitors and cancer in juvenile idiopathic arthritis: Disentangling the web. <i>Arthritis and Rheumatism</i> , 2012, 64, 966-969.	6.7	7
54	The Clinical Spectrum of Juvenile Idiopathic Arthritis in a Large Urban Population. <i>Current Rheumatology Reports</i> , 2012, 14, 116-120.	2.1	4

#	ARTICLE	IF	CITATIONS
55	Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1213-1223.	1.5	28
56	Efficacy and Safety of Rituximab in Pediatric Neuromyelitis Optica. <i>Journal of Child Neurology</i> , 2011, 26, 244-247.	0.7	30
57	Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010, 62, 335-344.	1.5	14
58	Toward the development of criteria for global flares in juvenile systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010, 62, 811-820.	1.5	24
59	Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010, 62, 950-959.	1.5	30
60	Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders. <i>Arthritis Care and Research</i> , 2010, 62, 1024-1028.	1.5	19
61	Response to Care needs to be taken when reviewing malignancy data reported from observational studies by Mariette, et al. <i>Arthritis Care and Research</i> , 2010, 63, n/a-n/a.	1.5	0
62	Contraception for adolescents with lupus. <i>Pediatric Rheumatology</i> , 2010, 8, 10.	0.9	6
63	Health-related Quality of Life and Its Relationship to Patient Disease Course in Childhood-onset Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 1536-1545.	1.0	61
64	Initial Validation of a Novel Protein Biomarker Panel for Active Pediatric Lupus Nephritis. <i>Pediatric Research</i> , 2009, 65, 530-536.	1.1	108
65	Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. <i>Arthritis and Rheumatism</i> , 2009, 60, 2772-2781.	6.7	121
66	Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. <i>Pediatric Nephrology</i> , 2008, 23, 403-412.	0.9	120
67	Physical function assessment tools in pediatric rheumatology. <i>Pediatric Rheumatology</i> , 2008, 6, 9.	0.9	20
68	Multicenter validation of a new quality of life measure in pediatric lupus. <i>Arthritis and Rheumatism</i> , 2007, 57, 1165-1173.	6.7	46
69	Quality of life in children with systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2005, 7, 447-452.	2.1	13
70	Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. <i>Journal of Pediatrics</i> , 2004, 145, 856-857.	0.9	91
71	Title is missing!. <i>Journal of Pediatric Orthopaedics</i> , 2003, 23, 114-118.	0.6	27
72	Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. <i>Journal of Pediatrics</i> , 2002, 140, 125-127.	0.9	45

#	ARTICLE	IF	CITATIONS
73	SYSTEMIC LUPUS ERYTHEMATOSUS IN A PEDIATRIC PATIENT WITH CONGENITAL ACQUIRED IMMUNODEFICIENCY SYNDROME. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 450-452.	1.1	10
74	Advances in the medical treatment of juvenile rheumatoid arthritis. <i>Current Opinion in Pediatrics</i> , 2000, 12, 72-75.	1.0	13
75	Levels of soluble fas/APO-1 /CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 1735-1737.	6.7	85
76	Expression and function of the murine CD95/FasR/APO-1 receptor in relation to B cell ontogeny. <i>European Journal of Immunology</i> , 1995, 25, 2940-2947.	1.6	52